Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$1.1 - $2.09 $14,919 - $28,346
-13,563 Reduced 26.88%
36,898 $40,000
Q2 2023

Aug 14, 2023

BUY
$0.89 - $3.33 $44,910 - $168,035
50,461 New
50,461 $105,000

Others Institutions Holding INKT

About MiNK Therapeutics, Inc.


  • Ticker INKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,775,100
  • Market Cap $24.7M
  • Description
  • MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...
More about INKT
Track This Portfolio

Track Oracle Investment Management Inc Portfolio

Follow Oracle Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oracle Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oracle Investment Management Inc with notifications on news.